Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for SOMAVERT
- Strict IGF-1 Control in Acromegaly
- Lipolytic Effects of GH in Human Subjects in Vivo
- Pasireotide LAR and Pegvisomant Study in Acromegaly
- Role of Growth Hormone Antagonism in Modulating Insulin Sensitivity in Subjects With Pre-diabetes
- Pegvisomant With Glucagon Test to Assess for Adult Growth Hormone Deficiency
- Effect of DPP4 Inhibition on Growth Hormone Secretion
- Acromegaly Combination Treatment Study
- Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients
- Tissue Biomarker for Pegvisomant Action
- Figitumumab Combined With Pegvisomant For Advanced Solid Tumors
- Long Term Use of Somavert (Pegvisomant) For A Regulatory Post Marketing Commitment Plan
- Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients
- Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant
- Growth Hormone During Fasting.Signaltransduktion in Muscle and Adipose Tissue and Changes in Intrahepatic Lipid Content
- Canadian Pegvisomant Compassionate Study In Acromegalic Patients
Clinical trials list
click for details